Top Page
Holista Colltech Limited
(Sydney:HCT)
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Holista Colltech Limited Business Overview & Revenue Model
Holista Colltech Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.60M | 5.95M | 8.24M | 8.02M | 7.11M |
| Gross Profit | 2.80M | 2.62M | 1.01M | 1.31M | 873.15K |
| EBITDA | 304.37K | -4.52M | -1.02M | -957.40K | -5.30M |
| Net Income | -84.21K | -4.81M | -1.45M | -1.26M | -5.48M |
Balance Sheet | |||||
| Total Assets | 3.34M | 3.35M | 5.52M | 6.93M | 8.05M |
| Cash, Cash Equivalents and Short-Term Investments | 21.72K | 59.77K | 117.53K | 1.21M | 2.73M |
| Total Debt | 1.77M | 1.57M | 1.22M | 890.32K | 942.70K |
| Total Liabilities | 6.71M | 6.74M | 3.96M | 3.95M | 3.41M |
| Stockholders Equity | -1.73M | -1.97M | 2.83M | 4.10M | 5.42M |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -411.67K | -1.19M | -1.72M | -3.90M |
| Operating Cash Flow | -1.01M | -407.12K | -1.11M | -1.68M | -3.87M |
| Investing Cash Flow | 692.12K | -46.70K | -105.69K | 50.35K | -80.75K |
| Financing Cash Flow | 116.24K | 418.42K | 120.85K | 109.49K | 6.58M |
Holista Colltech Limited Technical Analysis
Holista Colltech Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.65B | 0.16 | -63.14% | 2.08% | 16.38% | 0.82% | |
48 Neutral | AU$23.79M | ― | ― | -5.86% | 98.26% | ||
| ― | €11.17M | ― | -240.42% | ― | ― | ― | |
47 Neutral | AU$22.31M | ― | -33.40% | ― | -13.09% | -139.06% | |
34 Underperform | AU$8.86M | ― | -105.17% | ― | -3.82% | 51.47% | |
| ― | AU$5.99M | ― | ― | ― | ― | ||
42 Neutral | AU$5.10M | ― | -76.28% | ― | 5.01% | 74.84% |
Holista Colltech Limited Corporate Events
Holista Colltech Limited has appointed Mr. Leong Man Loong as the permanent Chief Executive Officer, following his interim leadership since January 2025. Mr. Leong’s strategic focus and commitment to the company’s recovery have been recognized by the Board, who have confirmed his role with a nominal remuneration of $1 per annum. This decision underscores Holista’s strategy to rebuild shareholder value and strengthen its market position in the health and wellness industry.
Holista Colltech Limited has announced the issuance of 49,281,936 fully paid ordinary shares following the conversion of convertible notes, as approved by its shareholders. This move, conducted without disclosure under Part 6D.2 of the Corporations Act, signifies compliance with relevant legislative provisions and indicates no undisclosed information, potentially impacting investor confidence and market positioning.
Holista Colltech Limited has announced the application for the quotation of 49,281,936 ordinary fully paid securities on the ASX, as part of previously announced transactions. This move is expected to enhance the company’s liquidity and market presence, potentially benefiting stakeholders by increasing the company’s visibility and access to capital.
Holista Colltech Limited announced at its AGM that it is in ongoing discussions with Regenerex regarding a licensing agreement for Nano-Collagen marketing, though no binding agreement has been reached yet. The company cautions investors against making decisions based on the assumption that an agreement will be finalized, highlighting the uncertainty of the negotiations’ outcome.
Holista Colltech Limited, a company listed on the Australian Securities Exchange under the code HCT, held its Annual General Meeting on May 29, 2025. The meeting’s resolutions were decided by poll, with the results showing strong support for most resolutions, including the election of directors and approval of various mandates and securities issues. The outcomes indicate a stable shareholder confidence in the company’s strategic decisions and governance.
Holista Colltech Limited has announced a strategic shift in its ovine collagen business, including the closure of its Collie facility and plans to establish a new modular production model. The company is focusing on developing nano-collagen for advanced medical applications, such as wound healing and bio-ink for organ printing, and has partnered with Akrivis Health Care to enhance its nano-collagen capabilities. Holista is also working on securing intellectual property rights and expanding its market presence through a proposed license agreement with Regenerex Pharma Inc. for international markets.
Holista Colltech Limited has announced the appointment of Yuen Keong Yee as a director, effective May 14, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, although the new director currently holds no securities in the company. The announcement is expected to have implications for the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.
Holista Colltech Limited has announced the appointment of Mr. Robert Gemelli and Mr. Sam Yee as Independent Non-Executive Directors, following the resignations of Mr. David Deloub and Ms. Loren King. This strategic change in leadership is expected to bring valuable expertise in biotech commercialization and capital markets, aiding the company in advancing its pipeline and focusing on corporate recovery. The new directors’ diverse backgrounds in various industries are anticipated to strengthen Holista’s board and support its mission to deliver sustainable, science-backed health and wellness solutions.
Holista Colltech Limited has responded to a price query from ASX, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company assures compliance with ASX Listing Rules and confirms that its board has authorized the responses provided.
Holista Colltech Limited has announced its Annual General Meeting scheduled for May 29, 2025, at Stantons International in West Perth. The meeting will cover the financial statements and reports for the year ending December 31, 2024, and include several resolutions such as the adoption of the remuneration report, election and re-election of directors, and ratification of prior securities issues. These resolutions are significant for the company’s governance and financial structuring, impacting shareholder interests and the company’s strategic direction.
Holista Colltech Limited has successfully resolved its regulatory issues with ASIC by completing a $900K penalty payment. The company raised $1.53 million through convertible notes to settle this penalty and support working capital. Despite facing increased manufacturing costs and cash flow challenges, Holista recorded $1.9 million in customer receipts and $1.8 million in group sales, largely driven by its Dietary Supplements Division. The company is now focused on corporate recovery, stabilizing operations, and strengthening its financial position.
Holista Colltech Limited has announced an update regarding the conversion of unquoted equity securities, specifically adjusting the amount of converting notes. This update reflects the company’s ongoing financial management and could have implications for its capital structure and investor relations.